Subsequent EventIn March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust. Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI. The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $100.0 million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $50.0 million milestone from DRI if TZIELD achieves a certain level of sales.

$ 100.0

Future Revenue from DRI

$ 50.0

Subsequent Events (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
Subsequent Events (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2019	Dec. 31, 2022	Mar. 15, 2023
Subsequent Event [Line Items]
Subsequent Event			Subsequent EventIn March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust. Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI. The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $100.0 million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $50.0 million milestone from DRI if TZIELD achieves a certain level of sales.
Incyte Corporation (Incyte) \| Incyte MGA012 Agreement
Subsequent Event [Line Items]
Non-refundable upfront payment		$ 150.0
DRI Healthcare Acquisitions LP (DRI) \| Subsequent Event
Subsequent Event [Line Items]
Upfront Payment from DRI Health Trust				$ 100.0
Milestone from DRI	$ 50.0
Future Revenue from DRI	$ 50.0